LIF Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IF, E |
---|---|
Primary Accession | P15018 |
Other Accession | NP_002300, 4504991 |
Reactivity | Human, Mouse, Rat |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | Predicted: 22 kDa Observed: 25 kDa |
Application Notes | LIF antibody can be used for detection of LIF by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunofluorescence starting at 20 µg/mL. |
Gene ID | 3976 |
---|---|
Target/Specificity | LIF; At least two isoforms of LIF are known to exist. |
Reconstitution & Storage | LIF antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | LIF Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | LIF |
---|---|
Synonyms | HILDA |
Function | LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes. |
Cellular Location | Secreted. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.
References
Trouillas M, Saucourt C, Guillotin B, et al. The LIF cytokine: towards adulthood. Eur. Cytokine Netw. 2009; 20:51-62.
Hilton DJ, Nicola NA and Metcalf D. Purification of a murine leukemia inhibitory factor from Krebs ascites cells. Anal. Biochem. 1988; 173:359-67.
Schemlzer CH, Burton LE and Tamony CM. Purification and partial characterization of recombinant human differentiation-stimulating factor. Protein Expr. Purif. 1990; 1:54-62
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.